Compare AUBN & CYPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AUBN | CYPH |
|---|---|---|
| Founded | 1907 | 2011 |
| Country | United States | United States |
| Employees | N/A | 6 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 82.3M | 73.4M |
| IPO Year | 1996 | N/A |
| Metric | AUBN | CYPH |
|---|---|---|
| Price | $25.09 | $0.67 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 3.1K | ★ 4.2M |
| Earning Date | 04-28-2026 | 05-13-2026 |
| Dividend Yield | ★ 4.61% | N/A |
| EPS Growth | ★ 13.66 | N/A |
| EPS | ★ 0.63 | N/A |
| Revenue | ★ $619,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $40.09 | ★ N/A |
| Revenue Growth | ★ 0.81 | N/A |
| 52 Week Low | $21.00 | $0.50 |
| 52 Week High | $29.00 | $3.70 |
| Indicator | AUBN | CYPH |
|---|---|---|
| Relative Strength Index (RSI) | 56.95 | 34.65 |
| Support Level | $24.61 | $0.56 |
| Resistance Level | $25.49 | $0.79 |
| Average True Range (ATR) | 0.27 | 0.16 |
| MACD | 0.10 | -0.05 |
| Stochastic Oscillator | 64.49 | 15.48 |
Auburn National Bancorp Inc operates as a bank holding company, which offers checking, savings, transaction deposit accounts and certificates of deposit, and is an active residential mortgage lender in its primary service area. The Bank's primary service area includes the cities of Auburn and Opelika, Alabama and nearby surrounding areas in East Alabama, predominantly in Lee County. The Bank also offers commercial, financial, agricultural, real estate construction and consumer loan products and other financial services. The Bank also provides automated teller machine (ATM) services in East Alabama and operates ATM machines. The Bank offers Visa Checkcards, which are debit cards. The Bank offers online banking, bill payment and other electronic banking services through its Internet website.
Cypherpunk Technologies Inc is a privacy technology company focused on implementing a digital asset treasury business anchored by Zcash, which is a cryptographic digital asset that operates on a decentralized, open-source blockchain network known as the Zcash Network. Through its subsidiary, the company is also engaged in developing novel therapies for patients with cancer. The group holds Zcash as part of its digital treasury business and has the following drug candidates under development in its biopharma business: Sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1; and a preclinical antibody program, FL-501, that is designed to treat cachexia-related indications.